Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
CNOOC
00883
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 71.18%11.8B | 59.99%44.4B | --28.54B | 31.68%16.42B | --6.9B | 2.76%27.75B | 1.42%12.47B | 32.54%27.01B | --12.29B | 198.88%20.37B |
| Operating income | 71.18%11.8B | 59.99%44.4B | 28.54B | 31.68%16.42B | 6.9B | 2.76%27.75B | 1.42%12.47B | 32.54%27.01B | 12.29B | 198.88%20.37B |
| Cost of sales | ---- | -58.46%-36.99B | ---- | -28.69%-13.54B | ---- | 0.65%-23.34B | 5.35%-10.52B | -28.59%-23.49B | ---11.12B | -189.74%-18.27B |
| Operating expenses | -75.85%-10.03B | -58.46%-36.99B | -24.12B | -28.69%-13.54B | -5.7B | 0.65%-23.34B | 5.35%-10.52B | -28.59%-23.49B | -11.12B | -189.74%-18.27B |
| Gross profit | 48.87%1.78B | 68.08%7.41B | 4.42B | 47.78%2.88B | 1.19B | 25.58%4.41B | 65.23%1.95B | 66.94%3.51B | 1.18B | 311.69%2.1B |
| Selling expenses | -190.89%-54.51M | -26.21%-777.43M | ---99.56M | -79.82%-368.57M | ---18.74M | -79.50%-615.97M | -90.06%-204.96M | -19.04%-343.16M | ---107.84M | -93.25%-288.26M |
| Administrative expenses | -27.77%-263.75M | -18.06%-1.48B | ---691.96M | 3.38%-500.06M | ---206.43M | -86.07%-1.26B | -65.32%-517.54M | -14.35%-675.75M | ---313.05M | -76.72%-590.97M |
| Research and development expenses | -37.01%-504.06M | -51.14%-2.14B | ---1.47B | -58.54%-859.67M | ---367.89M | -42.91%-1.42B | -217.89%-542.23M | -49.22%-991.96M | ---170.57M | -198.74%-664.76M |
| Profit from asset sales | -100.13%-235.18 | ---- | --184.65K | ---- | --184.65K | ---- | ---- | ---- | ---- | ---- |
| Revaluation surplus | 3,694.14%51.76M | ---- | --17.29M | ---- | ---1.44M | ---- | ---- | ---- | ---- | ---- |
| -Changes in the fair value of other assets | 3,694.14%51.76M | ---- | --17.29M | ---- | ---1.44M | ---- | ---- | ---- | ---- | ---- |
| Impairment and provision | -0.80%-155.12M | 127.47%36.27M | ---298.37M | 22.98%-23.54M | ---153.89M | -120.50%-132.05M | -50.97%-30.56M | -1,072.44%-59.88M | ---20.25M | 102.99%6.16M |
| -Other impairment is provision | -0.80%-155.12M | 127.47%36.27M | ---298.37M | 22.98%-23.54M | ---153.89M | -120.50%-132.05M | -50.97%-30.56M | -1,072.44%-59.88M | ---20.25M | 102.99%6.16M |
| Special items of operating profit | -6.48%46.6M | -62.48%82M | --123.37M | 566.86%39.56M | --49.83M | 132.30%218.54M | 102.93%5.93M | -563.47%-676.56M | ---202.58M | -12.60%145.98M |
| Operating profit | 89.25%822.85M | 159.31%3.13B | 1.81B | 77.09%1.17B | 434.79M | 57.73%1.21B | 80.60%658.77M | 7.38%764.2M | 364.78M | 529.11%711.66M |
| Financing income | -8.07%20.91M | ---- | --75.89M | ---- | --22.75M | ---- | ---- | ---- | ---- | ---- |
| Financing cost | -65.78%-209.86M | -105.87%-854.6M | ---598.98M | -28.76%-383.12M | ---126.6M | -25.63%-415.12M | -115.15%-297.54M | -406.68%-330.44M | ---138.29M | -161.13%-65.22M |
| Share of profits of associates | ---- | -863.53%-819K | ---- | 551.75%515K | ---- | 45.86%-85K | -533.33%-114K | 80.74%-157K | ---18K | 96.70%-815K |
| Special items of earning before tax | -1.00%5.37M | ---- | --9.29M | ---- | --5.42M | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | 64.37%562.53M | 187.31%2.27B | 1.3B | 117.10%783.99M | 342.23M | 82.24%790.2M | 59.46%361.12M | -32.84%433.6M | 226.47M | 917.81%645.63M |
| Tax | ---- | -427.79%-175.13M | ---- | -155.19%-31.01M | ---- | 1,400.76%53.43M | 40.39%56.18M | -92.57%3.56M | --40.02M | -0.41%47.91M |
| After-tax profit from continuing operations | 52.89%545.91M | 148.36%2.1B | 1.2B | 80.44%752.99M | 357.06M | 92.98%843.63M | 56.60%417.31M | -36.97%437.16M | 266.49M | 521.78%693.54M |
| Earning after tax | 52.89%545.91M | 148.36%2.1B | 1.2B | 80.44%752.99M | 357.06M | 92.98%843.63M | 56.60%417.31M | -36.97%437.16M | 266.49M | 521.78%693.54M |
| Minority profit | 36.26%172.91M | 145.45%619.59M | --512.43M | 70.53%287.03M | --126.9M | 76.79%252.43M | 40.30%168.32M | 7,371.79%142.79M | --119.97M | 106.71%1.91M |
| Profit attributable to shareholders | 62.05%373M | 149.60%1.48B | 684.6M | 87.14%465.96M | 230.17M | 100.83%591.2M | 69.94%248.99M | -57.44%294.38M | 146.52M | 393.92%691.63M |
| Basic earnings per share | 149.58%0.8326 | 87.12%0.2629 | 100.84%0.3336 | 69.89%0.1405 | -62.32%0.1661 | 0.0827 | 290.78%0.4408 | |||
| Diluted earnings per share | 149.58%0.8326 | 87.12%0.2629 | 100.84%0.3336 | 69.89%0.1405 | -62.32%0.1661 | 0.0827 | 290.78%0.4408 | |||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Luo Shenmei Accounting Firm, Rongcheng Accounting Firm (Special General Partnership) | -- | -- | -- | Luo Shenmei Accounting Firm, Rongcheng Accounting Firm (Special General Partnership) | -- | Luo Shenmei Accounting Firm, Rongcheng Accounting Firm (Special General Partnership) | -- | Luo Shenmei Accounting Firm, Rongcheng Accounting Firm (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.